Chargement en cours...
Bupropion Inhibits Serotonin Type 3AB Heteromeric Channels at Clinically Relevant Concentrations
Bupropion, a Food and Drug Administration–approved antidepressant and smoking cessation aid, blocks dopamine and norepinephrine reuptake transporters and noncompetitively inhibits nicotinic acetylcholine and serotonin (5-HT) type 3A receptors (5-HT(3A)Rs). 5-HT(3) receptors are pentameric ligand-gat...
Enregistré dans:
| Publié dans: | Mol Pharmacol |
|---|---|
| Auteurs principaux: | , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
The American Society for Pharmacology and Experimental Therapeutics
2020
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6978693/ https://ncbi.nlm.nih.gov/pubmed/31871303 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1124/mol.119.118349 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|